

(11) **EP 0 759 441 A2**(12) **EUROPEAN PATENT APPLICATION**(43) Date of publication:  
26.02.1997 Bulletin 1997/09(51) Int Cl.<sup>6</sup> **C07K 14/47, A61K 38/17**  
// (A61K38/17, 31:00),  
(A61K38/17, 31:445)(21) Application number: **96304723.8**(22) Date of filing: **26.06.1996**(84) Designated Contracting States:  
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL**  
**PT SE**  
Designated Extension States:  
**AL LT LV SI**(30) Priority: **30.06.1995 US 740**  
**27.10.1995 US 5910**  
**30.06.1995 US 752**  
**27.10.1995 US 5911**(71) Applicant: **ELI LILLY AND COMPANY**  
**Indianapolis, Indiana 46285 (US)**(72) Inventors:  
• **Bue-Valleskey, Juliana Maude**  
**Indianapolis, Indiana 46220 (US)**  
• **Helman, Mark Louis**  
**Indianapolis, Indiana 46250 (US)**  
• **Stephens, Thomas Wesley**  
**Indianapolis, Indiana 46226 (US)**  
• **Tinsley, Frank C.**  
**Indianapolis, Indiana 46256 (US)**(74) Representative: **Tapping, Kenneth George et al**  
**Lilly Industries Limited**  
**European Patent Operations**  
**Erl Wood Manor**  
**Windlesham Surrey GU20 6PH (GB)**(54) **Methods of treating neuropeptide Y-associated conditions**

(57) This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neu-

ropeptide Y which comprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

**BEST AVAILABLE COPY****EP 0 759 441 A2**